Harald Hampel
YOU?
Author Swipe
View article: Risk prediction of mild cognitive impairment using electronic health record data
Risk prediction of mild cognitive impairment using electronic health record data Open
INTRODUCTION Mild cognitive impairment (MCI) is underdiagnosed by primary care providers (PCPs), with detection rates as low as 6%–15%. Predictive models support the identification of individuals at risk, enabling timely intervention. METH…
View article: Precision medicine for epilepsy: challenges and perspectives for an optimized clinical care pathway
Precision medicine for epilepsy: challenges and perspectives for an optimized clinical care pathway Open
Epilepsies are a common, but heterogeneous group of brain disorders, characterized by an enduring predisposition to recurrent epileptic seizures. Recognizing epilepsies as a disease spectrum offers compelling opportunities to implement pre…
View article: Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data
Real-world health care costs and resource utilization associated with mild cognitive impairment in the United States: A retrospective cohort study of commercial and Medicare data Open
The economic burden of MCI was more than double that for similar individuals without MCI or dementia. Timely diagnosis and intervention are key to delaying progression to AD and reducing associated costs.
View article: Educational attainment, electroencephalographic rhythms, cortical structure, and cognitive performance over 2 years in older adults with subjective memory complaints and brain amyloidosis
Educational attainment, electroencephalographic rhythms, cortical structure, and cognitive performance over 2 years in older adults with subjective memory complaints and brain amyloidosis Open
INTRODUCTION We investigated whether older adults with subjective memory complaints (SMC) and amyloid‐β accumulation may show clinical progression over 2 years, as measured by resting‐state electroencephalographic (rsEEG), structural magne…
View article: Electroencephalogram features support the retrogenesis hypothesis of Alzheimer's disease: Exploratory comparison of brain changes in aging and childhood
Electroencephalogram features support the retrogenesis hypothesis of Alzheimer's disease: Exploratory comparison of brain changes in aging and childhood Open
Background The retrogenesis hypothesis (RH) suggests that the functional and cognitive decline observed in Alzheimer's disease dementia mirrors in reverse order the brain development during childhood and adolescence. Objective Equivalent e…
View article: GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy
GWAS meta-analysis of CSF Alzheimer's disease biomarkers 18,948 individuals reveal novel loci and genes regulating lipid metabolism, brain volume and autophagy Open
Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-Eu…
View article: Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true?
Alpha rhythm and Alzheimer’s disease: Has Hans Berger’s dream come true? Open
In this "centenary" paper, an expert panel revisited Hans Berger's groundbreaking discovery of human restingstate electroencephalographic (rsEEG) alpha rhythms (8-12 Hz) in 1924, his foresight of substantial clinical applications in patien…
View article: Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway
Defining benefit: Clinically and biologically meaningful outcomes in the next‐generation Alzheimer's disease clinical care pathway Open
To understand the potential benefits of emerging Alzheimer's disease (AD) therapies within and beyond clinical trial settings, there is a need to advance current outcome measurements into meaningful information relevant to all stakeholders…
View article: An observational multi‐clinic implementation science study to evaluate barriers and enablers of real‐world use of confirmatory blood‐based biomarkers for the diagnosis of early Alzheimer’s disease
An observational multi‐clinic implementation science study to evaluate barriers and enablers of real‐world use of confirmatory blood‐based biomarkers for the diagnosis of early Alzheimer’s disease Open
Background New innovations take a long time to be utilized into routine healthcare due to intrinsic and practical barriers. Implementation science can identify such barriers and offer potential solutions to speed up this process. Blood‐bas…
View article: Prediction of regional brain tau levels in early Alzheimer’s disease using plasma pTau217
Prediction of regional brain tau levels in early Alzheimer’s disease using plasma pTau217 Open
Background PET quantification of brain tau pathology aids in Alzheimer’s disease staging and patient screening. This study assesses whether the phosphorylated to nonphosphorylated plasma Tau217 ratio (pTau217R) predicts regional tau PET st…
View article: Advancing Early Detection of Alzheimer’s Disease in the Primary Care Setting in the United States
Advancing Early Detection of Alzheimer’s Disease in the Primary Care Setting in the United States Open
Background Recent advances in diagnostics have made it possible to identify early signs of the pathophysiological changes underlying Alzheimer’s Disease (AD) via blood tests. However, the use of blood‐based biomarkers (BBBMs) for the early…
View article: Expectation and perspectives of patients and physicians on new treatment for early Alzheimer Disease: Results of a physician survey and patient focus group interview
Expectation and perspectives of patients and physicians on new treatment for early Alzheimer Disease: Results of a physician survey and patient focus group interview Open
Background With the recent approval of disease modifying therapies (DMT) for early Alzheimer’s disease, there is a need for prescribing physicians to accurately communicate expectations of treatment effects to patients and their care partn…
View article: Risk Factors for Mild Cognitive Impairment: Prediction Models Developed with Electronic Health Record Data
Risk Factors for Mild Cognitive Impairment: Prediction Models Developed with Electronic Health Record Data Open
Background Timely identification of mild cognitive impairment (MCI) is key to early intervention. While primary care providers are the most likely entry point to detect early signs of MCI, their detection rates are low. Building upon a pub…
View article: Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease
Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease Open
BACKGROUND This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR), for sta…
View article: Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease
Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease Open
Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajecto…
View article: Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment
Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment Open
Plasma pTau181, a marker of amyloid and tau burden, was evaluated as a prognostic predictor of clinical decline and Alzheimer's disease (AD) progression of amyloid‐positive (Aβ+) patients with mild cognitive impairment (MCI). The training …
View article: Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease
Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease Open
BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid (CL) for Alz…
View article: Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force Open
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. Indeed, all three trials ha…
View article: Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary
Amyloid-related imaging abnormalities (ARIA) and their radiological, biological and clinical characteristics: a plain language summary Open
WHAT IS THIS SUMMARY ABOUT? This is a plain language summary of an article published in the journal Brain. People with Alzheimer's disease may receive treatments that target amyloid-β – a protein in the brain that is one of the key charact…
View article: Alzheimer's disease pathophysiology in the Retina
Alzheimer's disease pathophysiology in the Retina Open
The retina is an emerging CNS target for potential noninvasive diagnosis and tracking of Alzheimer's disease (AD). Studies have identified the pathological hallmarks of AD, including amyloid β-protein (Aβ) deposits and abnormal tau protein…
View article: The association between posterior resting-state EEG alpha rhythms and functional MRI connectivity in older adults with subjective memory complaint
The association between posterior resting-state EEG alpha rhythms and functional MRI connectivity in older adults with subjective memory complaint Open
Resting-state eyes-closed electroencephalographic (rsEEG) alpha rhythms are dominant in posterior cortical areas in healthy adults and are abnormal in subjective memory complaint (SMC) persons with Alzheimer's disease amyloidosis. This exp…
View article: Predicting clinical progression trajectories of early Alzheimer's disease patients
Predicting clinical progression trajectories of early Alzheimer's disease patients Open
BACKGROUND Models for forecasting individual clinical progression trajectories in early Alzheimer's disease (AD) are needed for optimizing clinical studies and patient monitoring. METHODS Prediction models were constructed using a clinical…
View article: The age-specific comorbidity burden of mild cognitive impairment: a US claims database study
The age-specific comorbidity burden of mild cognitive impairment: a US claims database study Open
View article: Age‐related relative comorbidity burden of mild cognitive impairment: A US database study
Age‐related relative comorbidity burden of mild cognitive impairment: A US database study Open
Background As novel therapies emerge, timely detection and diagnosis of early Alzheimer’s disease (AD) become increasingly relevant. While primary care would be the most suitable setting for early detection, diagnosis rates of mild cogniti…
View article: Education and amyloid load affect posterior lobe function in subjective memory complainers: an EEG‐fMRI study
Education and amyloid load affect posterior lobe function in subjective memory complainers: an EEG‐fMRI study Open
Background Indicators of cognitive reserve (CR) moderate the effect of brain pathophysiology on cognitive deficits in the Alzheimer’s Disease (AD) continuum. In a previous study on individuals with subjective memory complaint (SMCs), a con…
View article: Prognostic prediction of the longitudinal cognitive trajectory of amyloid‐positive patients with mild dementia
Prognostic prediction of the longitudinal cognitive trajectory of amyloid‐positive patients with mild dementia Open
Background Prediction of longitudinal cognitive decline for patients with mild dementia using baseline characteristics will be useful for designing optimal clinical trials and real‐world patient monitoring. This can be accomplished via mac…
View article: Detection of brain Tau deposition across Braak stages using plasma pTau181, MRI, and cognitive function assessments
Detection of brain Tau deposition across Braak stages using plasma pTau181, MRI, and cognitive function assessments Open
Background Non‐invasive methods for detecting neurofibrillary tangles that spread throughout the brain are needed for efficiently screening patients in Alzheimer’s disease (AD) clinical trials. This can be accomplished via machine‐learning…
View article: Development of a triage algorithm for mild cognitive impairment using electronic health record data
Development of a triage algorithm for mild cognitive impairment using electronic health record data Open
Background Timely detection and diagnosis of early‐stage Alzheimer’s disease (AD) become increasingly relevant with the introduction of new therapies. Electronic health records (EHR) data present an opportunity to identify cases with eleva…
View article: Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment
Correction: Differential response to donepezil in MRI subtypes of mild cognitive impairment Open
View article: Differential response to donepezil in MRI subtypes of mild cognitive impairment
Differential response to donepezil in MRI subtypes of mild cognitive impairment Open